Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress

Received GSK royalties of $57.0 million and net product revenues of $13.7 million in the third quarter of 2023Launched first-in-class therapy XACDURO® for treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of AcinetobacterAnnounced positive...

Related Keywords

United States ,Pavel Raifeld ,Jolla Pharmaceutical Company ,Armata Pharmaceuticals Inc ,Exchange Commission ,Nasdaq ,Theravance Respiratory Company ,Innoviva Inc ,Securities Exchange ,Glaxo Group Limited ,Global Antibiotic Research Development Partnership ,Chief Executive Officer ,Innoviva Strategic Opportunities ,Armata Pharmaceuticals ,Stephen Basso ,Chief Financial ,Innoviva Specialty Therapeutics ,Global Antibiotic Research ,Development Partnership ,Long Acting Beta ,Collaboration Agreement ,Entasis Therapeutics ,Private Securities Litigation Reform Act ,Securities Exchange Act ,Financial Condition ,Annual Report ,Quarterly Reports ,Consolidated Statements ,Months Ended September ,